Related Experiment Video
Updated: Aug 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Aspirin to prevent heart attack and stroke: what's the right dose?
1University of Arizona, Tucson 85718, USA. jamesdalen@yahoo.com
Insights
Determining the right aspirin dose for preventing heart attack and stroke is key. Studies suggest 160 mg daily is most effective for preventing both conditions while managing bleeding risks.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- The optimal aspirin dosage for preventing myocardial infarction (MI) and stroke remains uncertain despite numerous clinical trials.
- Commonly recommended doses in the US include 80, 160, or 325 mg daily.
- Balancing efficacy in preventing co-existing MI and stroke with the risk of major bleeding is crucial.
Purpose of the Study:
- To determine the most appropriate aspirin dose for the primary and secondary prevention of myocardial infarction and stroke.
- To evaluate the effectiveness of different aspirin doses across various patient populations and risk profiles.
- To compare the bleeding risk associated with different aspirin dosages.
Main Methods:
- Analysis of five randomized clinical trials comparing aspirin with placebo or no therapy.
- Evaluation of trial data based on aspirin dose, treatment duration, and participant baseline risk for stroke and MI.
- Assessment of aspirin's efficacy in men and women for primary and secondary prevention scenarios.
Main Results:
- 160 mg/day of aspirin consistently reduced MI risk in men.
- Lower doses (50-100 mg/day) were ineffective for MI prevention in women; doses must exceed 100 mg/day.
- 50 mg/day was effective for secondary prevention in patients with a history of stroke or TIA; 160 mg/day was effective for acute stroke prevention. Bleeding risk at 160 mg/day was similar to 80 mg/day.
Conclusions:
- The appropriate dose for primary and secondary prevention of stroke and MI appears to be 160 mg/day.
- This dose offers a balance between preventing cardiovascular events and managing bleeding risks.
- Further research may be needed to establish definitive primary prevention doses, particularly for women.
Abstract:
Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain. In the US, the doses most frequently recommended are 80, 160, or 325 mg per day. Because aspirin can cause major bleeding, the appropriate dose is the lowest dose that is effective in preventing both MI and stroke because these two diseases frequently co-exist. Five randomized clinical trials have compared aspirin with placebo or no therapy for the prevention of stroke and MI. These trials varied with regard to the dose of aspirin, the duration of treatment, and, most important, the populations selected for study varied in their baseline risk of stroke and MI. In men, 160 mg/day consistently lowered the risk of MI. In women, doses of 50 mg, 75, and 100 mg/day did not significantly decrease the risk of MI; therefore, the appropriate dose in women must exceed 100 mg/day. The appropriate dose for the primary prevention of stroke in men and women has not been established. Doses of 75 and 100 mg/day have been ineffective in men and women. The appropriate dose must be at least 160 mg/day. The lowest dose to prevent recurrent MI or death in patients with stable coronary artery disease (CAD) is 75 mg/day. In acute MI the lowest dose is 160 mg/day. In patients with a history of stroke or transient ischemic attack (TIA), 50 mg/day has been shown to be effective in men and women. In acute stroke, 160 mg/day is effective in preventing recurrent stroke or death. The risk of major bleeding with 160 mg/day is the same as with 80 mg/day: 1 to 2 cases per 1000 patient years of treatment, and the risk of fatal bleeding is the same with 80 and 160 mg/day. These studies indicate that the most appropriate dose for the primary and secondary prevention of stroke and MI is 160 mg/day.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Angina IV: Management